insulin sensitizer - biguanides

Description Results NMA

CV death NaN [NaN; NaN]

CV events NaN [NaN; NaN]

All-cause mortality NaN [NaN; NaN]

Stroke NaN [NaN; NaN]

Myocardial infarction ∞ [NaN; ∞]

macrovascular events 0.60 [0.40; 0.90]

CV death 2.97 [0.31; 28.30]

CV events 0.93 [0.69; 1.25]

All-cause mortality 1.48 [0.54; 4.09]

Stroke 0.99 [0.40; 2.44]

Myocardial infarction 1.11 [0.67; 1.83]

Microvascular 1.04 [0.75; 1.44]

microvascular and macrovascular events 0.92 [0.72; 1.18]

1.700 (n=50)

vs.

Placebo (n=50)

open

Parallel groups

Sample size: 50/50

Primary endpoint:

FU duration: 104

2.000 (n=196)

vs.

Placebo (n=194)

double blind

Parallel groups

Sample size: 196/194

Primary endpoint: microvascular and macrovascular morbidity and mortality

FU duration: 220

All-cause mortality 0.73 [0.55; 0.97]

Any diabetes-related outcomes 0.78 [0.65; 0.94]

CV events 2.88 [2.42; 3.44]

Stroke 0.56 [0.30; 1.02]

Myocardial infarction 0.78 [0.56; 1.09]

Microvascular 0.90 [0.58; 1.41]

Peripheral vascular disease 1.39 [0.53; 3.68]

Diabetes-related death 0.76 [0.51; 1.13]

2.550 (n=342)

vs.

SU/Insulin (n=951)

open

Parallel groups

Sample size: 342/951

Primary endpoint:

FU duration: 556

CV death NaN [NaN; NaN]

CV events NaN [NaN; NaN]

All-cause mortality NaN [NaN; NaN]

Stroke NaN [NaN; NaN]

Myocardial infarction NaN [NaN; NaN]

1.000 (n=24)

vs.

Glipizide (n=24)

Sample size: 24/24

Primary endpoint:

FU duration: 52